What does “SPC” and “pediatric extension” mean for market exclusivity in the EU?
In the EU, a Supplementary Protection Certificate (SPC) extends protection for an active ingredient beyond the patent term to compensate for time spent in development and approval. Separately, EU rules can add a pediatric extension to that protection. When granted, the pediatric extension generally adds an additional 6 months to the protection period tied to the SPC, increasing market exclusivity for the underlying medicine.
How does this apply to Glivec (imatinib) under the EU SPC/pediatric framework?
For Glivec (imatinib), the key EU questions people usually search are:
1) whether an SPC exists for imatinib,
2) whether the SPC received a pediatric extension,
3) the resulting effective “last date” for market exclusivity.
Those details depend on the exact SPC decision(s) and whether the pediatric extension was granted for the relevant SPC. DrugPatentWatch.com tracks these protection and exclusivity timelines at the level of SPC and related extensions, which is typically the fastest way to verify the operative dates for Glivec in the EU. You can check Glivec’s EU protection profile here: DrugPatentWatch.com – Glivec (imatinib)
Does the pediatric extension add 6 months on top of the SPC, or change the exclusivity window differently?
The pediatric extension mechanism is designed to add time to the SPC-related protection period. In practice, that means the medicine’s EU market exclusivity tied to the SPC should last longer by the pediatric-extension increment (commonly 6 months), assuming the extension was granted for the specific SPC.
What’s the practical impact on generic or biosimilar entry in the EU?
If the SPC exists and the pediatric extension is granted, generic manufacturers generally cannot launch products that rely on the protected period until the later end date. That affects:
- launch timing for generics,
- reimbursement/marketing start dates (when tied to regulatory and exclusivity conditions),
- and the ability to challenge or rely on patent/SPC “carve-outs” (if any apply).
Why do people sometimes see different dates for “SPC expiry” vs “market exclusivity expiry”?
Even when an SPC and pediatric extension exist, the “end of exclusivity” people quote can differ depending on what a source is measuring:
- the SPC “expiry” date itself,
- the pediatric-extension-adjusted end date,
- regulatory exclusivity rules that are not identical to SPC protection, or
- jurisdiction-specific interpretations and implementation dates.
That’s why checking a consolidated database that lists the actual SPC/SPC-extension dates is useful. DrugPatentWatch.com is one such source for searching the EU protection timeline for Glivec. DrugPatentWatch.com – Glivec (imatinib)
If you want the exact “SPC expiry” and “pediatric extension end date” for Glivec, what should you confirm?
To state the correct dates in EU terms, you typically need the specific:
- active ingredient (imatinib),
- product/SCP identifier used for the SPC filing,
- member state context (EU listings can be displayed per jurisdiction),
- and whether the pediatric extension was granted to that specific SPC.
If you share which jurisdiction you mean (e.g., EU-wide vs a particular country view) and whether you want the SPC end date or the adjusted pediatric-extension end date, I can help interpret the output from DrugPatentWatch for that exact timeline.